Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 4
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 4

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderMonte Rosa Therapeutics · 50
Strongest available pathTwist Bioscience · +23.5%
Widest latest marginVericel Corporation · 6.0%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1GLUE · Nasdaq

Monte Rosa Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2020Cambridge, Massachusetts$1.22B market cap
View full Companies Radar profile
50Moderate
Snapshot price$14.31as of page date
Monthly-close return-35.8%five-year window
FY2025 revenue$0.12BMonte Rosa Therapeutics, Inc.
Net margin-31.2%FY2025
P/E snapshot-7.6xone ratio, not a verdict
Prism attention8.6%share across these five
Filing track recordRevenue, USD billions
+63.5%
$0$0.0B$0.1B$0.1BFY2024: $0.076BFY2025: $0.124B20242025
FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 63.5%
52-week position46% through range
$4.60$25.77
News mentions472
Community mentions5partial coverage
U.S.-scope patents46
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal71/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2BEAM · Nasdaq

Beam Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2017Cambridge, Massachusetts$3.00B market cap
View full Companies Radar profile
48Cautious
Snapshot price$29.02as of page date
Monthly-close return-66.6%five-year window
FY2025 revenue$0.14BBeam Therapeutics Inc.
Net margin-57.2%FY2025
P/E snapshot-6.1xone ratio, not a verdict
Prism attention27.5%share across these five
Filing track recordRevenue, USD billions
+169.5%
$0$0.1B$0.3B$0.4BFY2021: $0.052BFY2022: $0.061BFY2023: $0.378BFY2024: $0.064BFY2025: $0.140B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 28.1%
52-week position58% through range
$16.02$38.26
News mentions1.5K
Community mentions103partial coverage
U.S.-scope patents557
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal75/100
Management stability90/100
Market position5/100
Capital-event signal49/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3TSHA · Nasdaq

Taysha Gene Therapies

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2020Dallas, Texas$1.86B market cap
View full Companies Radar profile
48Cautious
Snapshot price$5.70as of page date
Monthly-close return-69.4%five-year window
FY2025 revenue$0.01BTaysha Gene Therapies, Inc.
Net margin-1115.3%FY2025
P/E snapshot-11.9xone ratio, not a verdict
Prism attention13.1%share across these five
Filing track recordRevenue, USD billions
+290.6%
$0$0.0B$0.0B$0.0BFY2022: $0.003BFY2023: $0.015BFY2024: $0.008BFY2025: $0.010B2022202320242025
FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 57.5%
52-week position65% through range
$2.71$7.30
News mentions714
Community mentions5partial coverage
U.S.-scope patents0
Prism Insights

What sits behind the readiness signal

Observed risk 8/100higher means more observed risk
Earnings signal60/100
Management stability90/100
Market position3/100
Capital-event signal75/100
Innovation pulse16/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 8 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 3 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TWST · Nasdaq

Twist Bioscience

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Dover$8.69B market cap
View full Companies Radar profile
48Cautious
Snapshot price$132.1as of page date
Monthly-close return+23.5%five-year window
FY2025 revenue$0.38BTwist Bioscience Corp
Net margin-20.6%FY2025
P/E snapshot-208.5xone ratio, not a verdict
Prism attention34.0%share across these five
Filing track recordRevenue, USD billions
+184.6%
$0$0.1B$0.3B$0.4BFY2021: $0.132BFY2022: $0.204BFY2023: $0.245BFY2024: $0.313BFY2025: $0.377B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 29.9%
52-week position82% through range
$23.30$155.4
News mentions1.9K
Community mentions75partial coverage
U.S.-scope patents659
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal60/100
Management stability85/100
Market position6/100
Capital-event signal69/100
Innovation pulse7/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 5 lifetime product-launch events, 0 in the latest 360 days, and 3 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VCEL · Nasdaq

Vericel Corporation

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1989PLYMOUTH$2.07B market cap
View full Companies Radar profile
47Cautious
Snapshot price$40.50as of page date
Monthly-close return-17.0%five-year window
FY2025 revenue$0.28BVericel Corp
Net margin6.0%FY2025
P/E snapshot84.4xone ratio, not a verdict
Prism attention16.8%share across these five
Filing track recordRevenue, USD billions
+80.5%
$0$0.1B$0.2B$0.3BFY2021: $0.153BFY2022: $0.164BFY2023: $0.198BFY2024: $0.237BFY2025: $0.276B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.9%
52-week position57% through range
$28.95$49.32
News mentions920
Community mentions0partial coverage
U.S.-scope patents26
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal65/100
Management stability90/100
Market position0/100
Capital-event signal55/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Twist Bioscience
+23.5%
Vericel Corporation
-17.0%
Monte Rosa Therapeutics
-35.8%
Beam Therapeutics
-66.6%
Taysha Gene Therapies
-69.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Twist Bioscience
$0.38B
Vericel Corporation
$0.28B
Beam Therapeutics
$0.14B
Monte Rosa Therapeutics
$0.12B
Taysha Gene Therapies
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Vericel Corporation
6.0%
Twist Bioscience
-20.6%
Monte Rosa Therapeutics
-31.2%
Beam Therapeutics
-57.2%
Taysha Gene Therapies
-1115.3%

Prism news attention

Normalized share across these five names; attention is not quality.

Twist Bioscience
34.0%
Beam Therapeutics
27.5%
Vericel Corporation
16.8%
Taysha Gene Therapies
13.1%
Monte Rosa Therapeutics
8.6%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Twist Bioscience leads the conversation

It holds 34.0% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.38B.

Price path

Twist Bioscience leads the available price paths

Its monthly-close return is +23.5% for the five-year window. At the other end, Taysha Gene Therapies is -69.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Vericel Corporation has the widest latest margin

Its FY2025 net margin is 6.0%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Twist Bioscience shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -208.5x while its five-year window price return is +23.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · BEAM

Beam Therapeutics

1,504available Prism news records

Prism top themes

Price action & investor response
76
Capital allocation & transactions
31
Earnings & financial performance
26
Legal, arbitration & regulatory
15
Leadership & governance
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+17.4%364 latest 12m vs 310 prior 12m
2024-01: 27 mentions2024-02: 21 mentions2024-03: 10 mentions2024-04: 19 mentions2024-05: 31 mentions2024-06: 14 mentions2024-07: 15 mentions2024-08: 7 mentions2024-09: 13 mentions2024-10: 17 mentions2024-11: 34 mentions2024-12: 24 mentions2025-01: 25 mentions2025-02: 32 mentions2025-03: 38 mentions2025-04: 33 mentions2025-05: 43 mentions2025-06: 29 mentions2025-07: 14 mentions2025-08: 27 mentions2025-09: 37 mentions2025-10: 36 mentions2025-11: 34 mentions2025-12: 17 mentions2026-01: 45 mentions2026-02: 50 mentions2026-03: 25 mentions2026-04: 45 mentions2026-05: 28 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

95.5% positive+4.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 119crispr-cas9 67crispr applications 63rare disease clinical trials 49stem cell banking 49gene delivery systems 32rare disease treatment 31cell-based therapies 27

Keyword tag occurrences in available Prism news records.

Coverage: 2018-05-07–2026-06-19 · trend and themes shown through 2026-06
Areas of research · TWST

Twist Bioscience

1,858available Prism news records

Prism top themes

Earnings & financial performance
81
Price action & investor response
71
Capital allocation & transactions
18
Leadership & governance
11
Legal, arbitration & regulatory
8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+15.4%314 latest 12m vs 272 prior 12m
2024-01: 26 mentions2024-02: 31 mentions2024-03: 12 mentions2024-04: 13 mentions2024-05: 32 mentions2024-06: 22 mentions2024-07: 29 mentions2024-08: 20 mentions2024-09: 15 mentions2024-10: 28 mentions2024-11: 33 mentions2024-12: 9 mentions2025-01: 6 mentions2025-02: 43 mentions2025-03: 17 mentions2025-04: 26 mentions2025-05: 34 mentions2025-06: 12 mentions2025-07: 10 mentions2025-08: 29 mentions2025-09: 23 mentions2025-10: 11 mentions2025-11: 33 mentions2025-12: 17 mentions2026-01: 32 mentions2026-02: 56 mentions2026-03: 8 mentions2026-04: 45 mentions2026-05: 44 mentions2026-06: 6 mentions2024-012026-06

Machine-classified coverage tone

91.1% positive-3.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

diagnostic biotechnology 41synthetic biology 40enzyme engineering 24earnings report 22gene delivery systems 22crispr-cas9 15pharmacogenomics 15stock performance 15

Keyword tag occurrences in available Prism news records.

Coverage: 2010-12-18–2026-06-12 · trend and themes shown through 2026-06
Areas of research · VCEL

Vericel Corporation

920available Prism news records

Prism top themes

Earnings & financial performance
46
Price action & investor response
30
Capital allocation & transactions
18
Leadership & governance
14
Legal, arbitration & regulatory
1

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-61.6%123 latest 12m vs 320 prior 12m
2024-01: 2 mentions2024-02: 10 mentions2024-03: 11 mentions2024-04: 3 mentions2024-05: 11 mentions2024-06: 12 mentions2024-07: 9 mentions2024-08: 12 mentions2024-09: 2 mentions2024-10: 8 mentions2024-11: 6 mentions2024-12: 3 mentions2025-01: 5 mentions2025-02: 254 mentions2025-03: 6 mentions2025-04: 4 mentions2025-05: 8 mentions2025-06: 3 mentions2025-07: 3 mentions2025-08: 6 mentions2025-09: 10 mentions2025-10: 6 mentions2025-11: 11 mentions2025-12: 1 mentions2026-01: 14 mentions2026-02: 10 mentions2026-03: 15 mentions2026-04: 26 mentions2026-05: 19 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

90.8% positive-5.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stem cell banking 38cell-based therapies 15cell therapy 13stock performance 13biosimilar market entry 8stem cell transplantation 8gene therapy rare diseases 7pluripotent stem cells 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-10-30–2026-06-09 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

BEAM

Beam Therapeutics

103 mentions
Stock and valuation
45
Products, pricing and logistics
10
Workplace and hiring
4

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 103 records remained after filtering.

TWST

Twist Bioscience

75 mentions
Stock and valuation
33
Products, pricing and logistics
10
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 75 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

GLUE

Monte Rosa Therapeutics

through 2025-05-27
Leadership changes 3Business contracts 2Earnings releases 1
  1. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monte Rosa Therapeutics $159.49 million 1.53 -$135.35 million $0.08 49.63 Aptose Biosciences N/A N/A -$51.21 million ($89.19) N/A

  2. Business contracts

    Novartis has agreed to pay Monte Rosa $150 million up front, and the latter could bank as much as $2.1 billion in development, regulatory, and sales milestone rewards, beginning upon the start of phase II work, as well as tiered royalties on ex-U.S. net sales.

  3. Leadership changes

    Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer, joined the Company as General Counsel and has provided general legal support, including work on intellectual property matters and external business transactions.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BEAM

Beam Therapeutics

through 2025-10-28
Earnings releases 7Leadership changes 2M&A 2Regulatory 2Listing / IPO 1
  1. Earnings releases

    This company is expected to post quarterly loss of $0.98 per share in its upcoming report, which represents a year-over-year change of +16.2%.

  2. Regulatory

    Beam Therapeutics announced on Aug. 14 that the FDA granted regenerative medicine advanced therapy designation status for Beam-101.

  3. M&A

    Beam adds targeting tech with $440M Guide buy

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TSHA

Taysha Gene Therapies

through 2026-04-18
Company announcements 14Earnings releases 9Listing / IPO 2Regulatory 2
  1. Listing / IPO

    Taysha Gene Therapies completed its initial public offering in May 2021.

  2. Company announcements

    today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the Company’s common stock and an option to purchase 92,400 shares of the Company's common stock in connection with their employment.

  3. Earnings releases

    Based on Taysha Gene Therapies’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $32.73 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TWST

Twist Bioscience

through 2026-05-04
Earnings releases 40Leadership changes 5Company announcements 4Asset acquisitions 1Board updates 1
  1. Earnings releases

    Twist Bioscience Corporation (NASDAQ: TWST ), a mid-cap growth and value biotech company, today announced financial results and business highlights for the second quarter fiscal 2026 ended March 31, 2026.

  2. Board updates

    Stockholders voted on the election of three directors to serve until the 2029 annual meeting of stockholders (and until their successors are elected and qualified, or until earlier resignation or removal). The nominees were Keith Crandell , Jan Johannessen , and Trynka Shineman Blake.

  3. Company announcements

    The company is seeing significant growth in AI-enabled drug discovery, with orders from AI discovery projects growing by more than $25 million compared to fiscal 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VCEL

Vericel Corporation

through 2026-01-13
Earnings releases 28Leadership changes 2Listing / IPO 1
  1. Earnings releases

    Total net revenue expected to be approximately $276 million , with MACI ® net revenue of $239.5 million and Burn Care net revenue of $36.5 million

  2. Listing / IPO

    BOSTON – Cambridge, Mass.-based Vericel Corp. reported the closing of an underwritten public offering of more than 5.7 million shares of its common stock at a price of $13 per share. The gross proceeds, expected to be about $74.8 million, will be used for general corporate purposes and to expand its business by in-licensing or acquiring assets.

  3. Leadership changes

    CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 16–23. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Monte Rosa Therapeutics has the widest attention-readiness rank gap

It ranks #5 by measured news attention (8.6%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Monte Rosa Therapeutics in Companies Radar

Taysha Gene Therapies shows a price-operating divergence to inspect

Its displayed filing-revenue change is +290.6% while its available monthly-close return is -69.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Taysha Gene Therapies in Companies Radar
Explanations

Attention measures coverage volume, not quality

Twist Bioscience's 34.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Twist Bioscience in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Monte Rosa Therapeutics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 50/100 score.

Open Monte Rosa Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon